About Laprophan
Laprophan is a Healthcare company based in Casablanca (Morocco) founded in 1949. Generic drugs are manufactured by Laprophan in Casablanca, Morocco. Laprophan has raised $71.28 million across 1 funding round from investors including FMO, Proparco and Mediterrania Capital Partners. Laprophan has completed 2 acquisitions, including Amanys Pharma and Rivopharm. Its chief executive, as recorded, is Farid Bennis. Laprophan offers products and services including Pharmaceutical Specialities and Research and Development Services. Its focus areas include Traditional Pharmaceuticals. Its legal entity is Laboratoires Laprophan.
Company details
Laprophan was founded in 1949 and is headquartered in Casablanca, Morocco. Operations are focused on the pharmaceutical sector, where generic drugs are produced for various therapeutic areas. Manufacturing processes are conducted at facilities in Morocco, serving regional and international markets. Leadership is provided by CEO Farid Bennis, overseeing production and distribution activities in the generics industry.
- Headquarters Casablanca, Morocco
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website laprophan.com
- Social LinkedIn X Facebook
- Legal Name Laboratoires Laprophan
- Total Equity Funding$71.28M (USD)
in 1 rounds
- Latest Funding Round$71.28M (USD), Series C
Feb 2023
- InvestorsFMO
& 3 more
- Investments & AcquisitionsAmanys Pharma
& 1 more
Products & Services of Laprophan
Laprophan offers a comprehensive portfolio of products and services, including Pharmaceutical Specialities and Research and Development Services.
Various pharmaceutical products are developed and distributed for treating health conditions, with a focus on innovation and accessibility.
Research in pharmaceuticals is conducted to create new therapeutic solutions, often through partnerships and internal efforts.
Funding Insights of Laprophan
Laprophan has successfully raised a total of $71.28M through 1 strategic funding round. The most recent funding activity was a Series C round of $71.28 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $71.28M
- Total Rounds 1
- Last Round Series C — $71.28M
- First Round $71.28M
(Feb 2023)
- Investors Count 4
All 1 funding rounds of Laprophan with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2023 | $71.28M | Series C | – | Mediterrania Capital Partners |
4 investors in total: 4 institutional.
Investors in Laprophan
Laprophan has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include FMO, Proparco and Mediterrania Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| mcapitalp.com | ||||
Development financing is provided for entrepreneurial ventures in emerging markets. | 1970 | fmo.nl | The Hague, Netherlands | |
Economic development investments are financed through specialized solutions by Proparco. | 1977 | proparco.fr | Paris, France | |
Private equity firm focused on growth equities | deginvest.de | Cologne, Germany |
Investor details for Laprophan
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Laprophan
1 people are tracked at Laprophan (1 in leadership).
| Name | Role | Group |
|---|---|---|
Farid Bennis | CEO | Leadership |
Complete people profiles for Laprophan
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Laprophan
Laprophan has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Amanys Pharma and Rivopharm.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Pharmaceutical production and distribution of generic drugs for psychiatric, antidiabetic, and other therapies. | rivopharm.ch | 0 | Oct 2025 | •••• | ||
Drugs for multiple therapeutic areas are manufactured through R&D. | amanyspharma.com | Casablanca, Morocco | 2011 | Nov 2023 | •••• |
Complete acquisition details for Laprophan
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Laprophan
4 dated milestones of Laprophan across 76 years, from founding to its latest funding, stage changes and deals.
- Founded Laprophan is founded.
- Funding First funding round of $71.3M.
- Acquisition Acquires Amanys Pharma.
- Acquisition Acquires Rivopharm.
Web traffic of Laprophan
The website of Laprophan (laprophan.com) receives about 2.8K visits a month and ranks #9,491,152 among all websites worldwide, #7,695 in Biotechnology and Pharmaceuticals.
- Monthly visits2.8K
▲ 45.4% vs previous month
- Global rank#9,491,152
among all websites
- Category rank#7,695
Health · Biotechnology and Pharmaceuticals
- Bounce rate56%
- Pages per visit1.2
- Average visit13 sec
- DevicesDesktop 26% · Mobile 74%
Websites whose visitors overlap most with Laprophan. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
cooperpharma.ma | cooperpharma.ma | 100% | #4,337,872 | – | |
novartis.fr | novartis.fr | 86% | – | ||
medicament.ma | medicament.ma | 53% | #58,759 | – | |
| kinray.com | 52% | View details | |||
doctinews.com | doctinews.com | 52% | #3,557,180 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Laprophan
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Laprophan
Complete news archive for Laprophan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Laprophan
Laprophan was founded in 1949 and raised its 1st funding round 74 years after it was founded.
Laprophan is headquartered in Casablanca, Morocco.
Farid Bennis is the CEO of Laprophan, as recorded in our data.
Laprophan is a funded company, having raised a total of $71.28M across 1 funding round to date. The company's 1st funding round was a Series C of $71.28M, raised on Feb 2023.
Laprophan was founded in 1949 and is headquartered in Casablanca, Morocco. Operations are focused on the pharmaceutical sector, where generic drugs are produced for various therapeutic areas. Manufacturing processes are conducted at facilities in Morocco, serving regional and international markets. Leadership is provided by CEO Farid Bennis, overseeing production and distribution activities in the generics industry.
Laprophan offers Pharmaceutical Specialities and Research and Development Services.
Laprophan has made 2 acquisitions, including Amanys Pharma, and Rivopharm.
Laprophan operates through Laboratoires Laprophan.